A 32-year-old woman from Delhi presents with a 14-day history of fever, chills, and abdominal pain. She was treated empirically with fluoroquinolone 3 days ago, but fever persists. Blood culture from day 1 of admission (before antibiotics) grew *Salmonella typhi* susceptible to all first-line agents. Repeat blood culture today is negative. Her temperature is 38.8°C, and she has mild hepatomegaly. What is the most appropriate next step in management?

Explanation

## Management of Enteric Fever: Antibiotic Selection and Duration ### Clinical Context This patient has confirmed *Salmonella typhi* enteric fever with: - Positive blood culture on day 1 (diagnostic) - Negative repeat culture on day 14 (indicates bacteremia clearance) - Persistent fever despite 3 days of fluoroquinolone (expected — fever may persist 3–5 days even with appropriate therapy) - Organism susceptible to all first-line agents **Key Point:** Defervescence in enteric fever typically occurs 3–5 days after starting appropriate antibiotics; persistent fever at day 14 does NOT necessarily indicate treatment failure if blood cultures have cleared. ### First-Line Antibiotic Regimens for Enteric Fever | Drug Class | Agent | Dosage | Duration | Notes | |-----------|-------|--------|----------|-------| | **Fluoroquinolone** | Ciprofloxacin/Ofloxacin | 500–750 mg BD | 5–7 days | First-line in uncomplicated cases; resistance emerging in India | | **3rd-gen Cephalosporin** | Ceftriaxone | 1–2 g IV/IM BD | 7–14 days | Gold standard for severe/complicated cases; preferred in pregnancy | | **Macrolide** | Azithromycin | 500 mg–1 g daily | 5–7 days | Emerging resistance; used in fluoroquinolone-resistant strains | | ~~Chloramphenicol~~ | ~~Chloramphenicol~~ | ~~Obsolete~~ | ~~Obsolete~~ | Rarely used; high relapse rates; bone marrow toxicity | **High-Yield:** In India, fluoroquinolone resistance in *S. typhi* has increased significantly (>60% in some regions). Even susceptible isolates may show **reduced susceptibility** (MIC elevation), leading to clinical failures despite in vitro susceptibility. ### Why Switch to Ceftriaxone? 1. **Superior CNS penetration** — cephalosporins cross the blood–brain barrier better than fluoroquinolones; important for preventing complications like meningitis. 2. **Reduced relapse rates** — cephalosporins have lower relapse rates (~5%) compared to fluoroquinolones (~10–15%), especially in India. 3. **Emerging resistance** — fluoroquinolone-resistant and reduced-susceptibility *S. typhi* are endemic in India; cephalosporins remain reliable. 4. **Duration** — 7–14 days of cephalosporin is standard; 5–7 days of fluoroquinolone is adequate only in uncomplicated cases with rapid defervescence. **Clinical Pearl:** The patient is on day 14 of illness with persistent fever. Switching to a cephalosporin for the remaining duration (7–14 days total) reduces relapse risk and is the guideline-recommended approach for confirmed *S. typhi* in endemic areas. ### Decision Algorithm ```mermaid flowchart TD A["Confirmed S. typhi enteric fever"]:::outcome --> B{"Severity & complications?"}:::decision B -->|"Uncomplicated, rapid defervescence"| C["Fluoroquinolone 5–7 days"]:::action B -->|"Severe, CNS involvement, or persistent fever"| D["Cephalosporin 7–14 days"]:::action B -->|"Fluoroquinolone-resistant"| E["Cephalosporin or Azithromycin"]:::action F["Negative repeat blood culture"] --> G{"Fever resolved?"}:::decision G -->|"Yes"| H["Continue current agent to completion"]:::action G -->|"No, persistent fever at day 14"| D D --> I["Reassess for complications"]:::action I --> J["Imaging if focal signs"]:::action ``` **Mnemonic: CEPHALOSPORIN for Complicated/Chronic** — Use cephalosporins when fever is prolonged, CNS involvement is suspected, or resistance is likely. ### Why NOT the Other Options? **Continuing fluoroquinolone:** While the organism is susceptible, fluoroquinolone resistance/reduced susceptibility is prevalent in India. Switching to a cephalosporin reduces relapse risk and provides better CNS penetration for any occult complications. **Adding chloramphenicol:** Chloramphenicol is obsolete for enteric fever due to high relapse rates (~20–30%), bone marrow toxicity, and availability of superior agents. It is no longer recommended. **Imaging without changing antibiotics:** While imaging may be warranted if complications are suspected (e.g., perforation, abscess), the primary issue is antibiotic selection. Imaging is adjunctive, not the next step.